NCT01571648View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 1, 2012

Primary Completion Date

January 1, 2013

Study Completion Date

January 1, 2013

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Oral azacitidine

Patients will receive 300 mg dose of oral azacitidine administered once daily for the first 21 days of each 28-day treatment cycle.

Trial Locations (5)

Unknown

Celgene Trial Site, Fukuoka

Celgene Trial Site, Hiroshima

Celgene Trial Site, Nagoya

Celgene Trial Site, Osaka

Celgene Trial Site, Tokyo

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY